We found a gefitinib mimetic, N-(2-bromo-5-(trifluoromethyl)phenyl)-6-methoxy-7-(3- (piperidin-1-yl)propoxy)quinazolin-4-amine (hereafter, V1801), moderately inhibited EGFR kinase activity but significantly suppressed cell proliferation and induced apoptosis in T790M EGFR-harboring non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Here, EGFR is linked to non-small cell lung carcinoma.